Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conjugates by integrating orthogonal microtubule inhibition and high-linear-energy-transfer alpha irradiation.”
Title: Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conjugates
Authors: Anil P. Bidkar, Scott Bidlingmaier, Anju Wadhwa, Ellis Mayne, Athira Raveendran, Shubhankar Naik, Cheng Xue, Megha Basak, Kondapa Naidu Bobba, Bonell Patiño-Escobar, Nancy Greenland, Juan Antonio Camara Serrano, Veronica Steri, Jonathan Chou, Arun Wiita, Jiang He, David M. Wilson, Rahul Aggarwal, Henry F. VanBrocklin, Youngho Seo, Bin Liu, and Robert R. Flavell
You can read the Full Article in Clinical Cancer Research.
You can find more posts featuring Robert Orlowski on OncoDaily.
